The effect of Oxaliplatin in leading to apoptosis of intestinal cancer cells byinducing PUMA protein expression through reactive oxygen species

Abstract

Previous studies demonstrated Oxaliplatin, a drug used in treating intestinal cancers by inducing cancer cell apoptosis
regulated by p53 upregulated modulator of apoptosis (PUMA) protein gene expression. Increasing the reactive
oxygen species (ROS) level is possible to speed up the expression of PUMA protein in Oxaliplatin. This study aims
to investigate the effect of Oxaliplatin in intestinal cancer cells, leading to its apoptosis by inducing PUMA protein
expression through ROS, compared to Cisplatin and PBS. The result of the study will provide important insight into the
preclinical effectiveness of Oxaliplatin in intestinal cancer cells, and it also testifies to the underlying mechanism of this
drug. Future studies should focus on investigating drug combinations with Oxaliplatin that provides synergism toward
the disease and decreases its toxicity.